author-photo

Howard Gurney

Macquarie University
Westmead Hospital
University of Sydney

288

Papers

12805

Citations

Citation Trend

Filter By

Papers (216) Sort By

Journal Conference Others

Patient Preference or Indifference: Learning from the CABADOC Study.

2021 European Urology
Show All
- Source
- Cite
- Save
Citations (0)
661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
MP41-12 AVELUMAB FIRST-LINE MAINTENANCE PLUS BEST SUPPORTIVE CARE VS BEST SUPPORTIVE CARE ALONE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF TIME TO END OF NEXT-LINE THERAPY IN JAVELIN BLADDER 100

2021 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial

2021 BMJ Open
Show All
- Source
- Cite
- Save
Citations (1)
KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Health-Related Quality of Life (HRQoL) in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1

2021
Show All
- Source
- Cite
- Save
Citations (0)
Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)